Zusammenfassung
Die chronische Bronchitis ist Teil und Vorstufe der komplexen Erkrankung COPD, die meist auf Zigarettenrauchen zurückzuführen ist. Dazu kommt aber noch eine besondere Empfindlichkeit, möglicherweise bedingt durch genetische Faktoren oder zusätzliche Risikofaktoren. Entzündliche Veränderungen der Schleimhaut und der Bronchialwand führen auch zu einer Schädigung der Verbindungen von Atemwegen und Lungenparenchym. Chronische Bronchitis, fibrosierende Bronchiolitis und Emphysem sind die 3 pathologischen Säulen der Erkrankung, die unterschiedlich ausgeprägt sein können und klinisch unterschiedliche Erscheinungsbilder begründen. Die Behandlung beruht auf langwirksamen Bronchodilatatoren, sowie Kombinationen von derartigen, zumeist inhalativen Medikamenten. Zur Verschlechterung der Erkrankung tragen v. a. intermittierende Exazerbationen bei, die eine Änderung und Intensivierung der Therapie, gelegentlich einschließlich einer Beatmung bedürfen. Eine Reihe von nichtpharmakologischen Maßnahmen wie Nikotinentwöhnung, Rehabilitation, hochkalorische Ernährung, O2-Therapie, Heimbeatmung, Lungenvolumenreduktion und evtl. Lungentransplantation kommen für die Patienten in Frage und sollten individuell zum jeweils richtigen Zeitpunkt angeboten werden.
Abstract
Chronic bronchitis is part and precursor of COPD, a complex disease triggered mostly by exposure to cigarette smoke. However COPD develops only in patients with specific susceptibility probably determined by genetic factors or additional risk factors. A specific type of inflammation resides in the bronchial and bronchiolar walls, that infers damage not only to airway structure but also to surrounding alveolar attachments and thus to the lung parenchyma. Chronic bronchitis, fibrosing bronchiolitis and emphysema constitute the three main stems of pathology of the disease but may coexist with varying extent. The clinical picture is therefore quite variable. Treatment exists largely in bronchodilation combining different mechanisms and using long acting drugs usually applied by inhalation. Acute exacerbations promote progression of the disease, which must be counteracted by adaptation and intensification of therapy, in some cases including non invasive or invasive ventilation. Several non-pharmacologic measures such as smoking cessation, rehabilitation, nutritional support, long term oxygen therapy, lung volume reduction and possibly lung transplantation may be available for appropriate patients and have to be considered.
Literatur
Report of the Medical Research Council Working Party (1981) Long term domiciliary oxygen in chronic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1: 681–685
(2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343: 1902–1909
Aoshiba K, Yokohori N, Nagai A (2003) Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28: 555–562
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297–1303
Burrows B, Knudson RJ, Cline MG, Lebowitz MD (1977) Quantitative relationship between cigarette smoking and ventilatory function. Am Rev Respir Dis 115: 195–205
Calverley P, Pauwels R, Vestbo J et al. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449–456
Calverley PM (2000) The future for tiotropium. Chest 117: 67S–69S
Calverley PM, Georgopoulos D (1998) Chronic obstructive pulmonary disease: symptoms and signs. In: Postma DS, Siafakas NM (eds) Management of chronic obstructive pulmonary disease. European Respiratory Monograph, pp 6–24
Celli BR, Cote CG, Marin JM et al. (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350: 1005–1012
Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G (1996) Woodsmoke exposure and risk for obstructive airways disease among women. Chest 109: 115–119
Fiore MC (2000) US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 45: 1200–1262
Fishman A, Martinez F, Naunheim K et al. (2003) A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348: 2059–2073
Fletcher CM, Peto R (1977) The natural history of chronic airflow obstruction. BMJ 1: 1645–1648
Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL (1996) Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9: 431–435
Gillissen A (2000) Die chronisch obstruktive Lungenerkrankung. UNI-MED, Bremen, S 1–157
NOTT Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Ann Intern Med 93: 191–198
Hansel TT, Barnes PJ (2004) An atlas of chronic obstructive pulmonary disease COPD. Parthenon, London, pp 1–290
Hogg JC, Chu F, Utokaparch S et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–2653
Kerstjens HA, Brand PL, Postma DS (1996) Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: S266–272
Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ (2000) Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1136–1142
Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436–1442
O’Donnell DE, Fluge T, Gerken F et al. (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23: 832–840
O’Donnell DE, Revill SM, Webb KA (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 770–777
O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA (2004) Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24: 86–94
Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340: 1948–1953
Reid L (1960) Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 15: 132–141
Rennard SI (2004) Treatment of stable chronic obstructive pulmonary disease. Lancet 364: 791–802
Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, Abel J, Niewoehner DE (1987) Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 107: 305–309
Saetta M, Turato G, Baraldo S et al. (2000) Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 161: 1016–1021
Schols AM, Slangen J, Volovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1791–1797
Shoup R, Dalsky G, Warner S et al. (1997) Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J 10: 1576–1580
Silagy C, Stead L (2001) Physician advice for smoking cessation. Cochrane Database Syst Rev 2: CD000165
Takeyama K, Dabbagh K, Lee HM et al. (1999) Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 96: 3081–3086
Vestbo J (2004) What is an exacerbation of COPD. Eur Respir Rev 13: 6–13
Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353: 1819–1823
Worth H, Buhl R, Cegla U et al. (2002) Guidelines for the diagnosis and treatment of chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur pneumologie. Pneumologie 56: 704–738
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wirtz, H.R. Chronische Bronchitis, COPD. Internist 46, 175–194 (2005). https://doi.org/10.1007/s00108-004-1335-z
Issue Date:
DOI: https://doi.org/10.1007/s00108-004-1335-z
Schlüsselwörter
- Chronische Bronchitis
- Chronisch-obstruktive Lungenerkrankung
- Emphysem
- Obstruktive Bronchiolitis
- Bronchodilatatoren